The positive view is that Inspyr's drug platforms will show value and additional investment will be needed to take the company to higher value. The negative is that the shares are needed to pay off convertible notes by existing investors and will result in dilution and a RS at a later date. Take your pick!
News 
Market Data 
Discover 
